Siemens Healthineers raises the forecast again thanks to corona tests
The sale of rapid corona tests has boosted the business of Siemens’ medical technology division for longer than expected. Siemens Healthineers therefore again raised its sales and profit expectations for the current 2021/22 fiscal year on Wednesday: The Sales volume will be effective at the end of September on a like-for-like basis 5.5 to 7.5 percent above the previous year’s level lie; so far, the Siemens subsidiary had expected three to five percent. The antigen tests alone are said to contribute 1.3 million euros, 600 million more than originally thought. That adjusted earnings per shareby which Siemens Healthineers measures its success 2.25 to 2.35 (previously 2.18 to 2.30) euros ealso be higher.
Analysts had previously expected an average increase in sales of 4.4 percent and earnings per share of EUR 2.28. In the second quarter, the Sales volume – also thanks to the takeover of the US cancer specialist Varian – by 38 percent 5.46 billion eurosthat adjusted earnings before interest and taxes (EBIT) improved by 47 percent 980 million euros. “Our business has continued to prove very resilient in the face of unprecedented challenges,” said CEO Bernd Montag.